Ivantis secures $25 million in funding for commercialization of Hydrus microstent

Ivantis has secured $25 million in Series C funding for U.S. commercialization of the Hydrus microstent, according to a company press release.The Hydrus microstent, which is about the size of an eyelash, is expected to be approved by the FDA in 2018, the release said. It is designed to reduce a glaucoma patient’s IOP by re-establishing the natural outflow pathway, which is done through a minimally invasive microsurgical procedure.

Full Story →